3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
20
Vitamin D Deficiency
17
Prostatic Neoplasms
14
Neoplasms
9
Polycystic Ovary Syndrome
8
Colonic Neoplasms
8
Rectal Neoplasms
6
Colorectal Neoplasms
6
Myelodysplastic Syndromes
5
Osteoporosis
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Cardiovascular Diseases
4
Warts
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Brain Neoplasms
3
Adenomatous Polyps
3
Pathologic Processes
2
Pain
2
Obesity
2
Myeloproliferative Disorders
2
Myelodysplastic-Myeloproliferative Diseases
2
Musculoskeletal Diseases
2
Melanoma
2
Male Urogenital Diseases
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Interventions
Cyclophosphamide
117
Rituximab
115
fludarabine phosphate
79
Peripheral Blood Stem Cell Transplantation
71
Mycophenolic Acid
55
Whole-Body Irradiation
52
Filgrastim
49
Tacrolimus
43
Cyclosporine
43
Radiotherapy
41
Busulfan
41
Antilymphocyte Serum
38
Etoposide
36
Melphalan
34
Lenalidomide
31
Methotrexate
25
fludarabine
23
Cord Blood Stem Cell Transplantation
22
Bortezomib
20
Flow Cytometry
19
Cytarabine
19
Methylprednisolone
18
Bendamustine Hydrochloride
18
obinutuzumab
17
Prednisone
15
Granulocyte Colony-Stimulating Factor
15
Carmustine
15
sargramostim
14
orelabrutinib
14
Therapeutics
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, B-Cell, Marginal Zone
×
Cholecalciferol
×
Clear all
NCT03078855
2024-09-04
ILyAD
University of Rochester
Phase 3
Completed
211 enrolled
13 charts